cosa succede.... in pre è a 1.15.
Regulus Therapeutics (NASDAQ:RGLS) resumes trading after a halt, -32.3% AH after reporting a larger than expected Q1 loss, a 96%*Y/Y decline in revenues, and a 30% workforce reduction.
In a major management shakeup, President and CEO Paul Grint resigns, to be replaced by COO Jay Hagan effective immediately, and VP*of finance and accounting Daniel Chevallard is promoted to CFO.
(da SeekingAlpha)